Search Results
Your search for The ASCO Post,The ASCO Post matches 17618 pages
Showing 15301 - 15350Expert Point of View: Solange Peters, MD, PhD
The IMPRESS trial asks a simple question: Should you continue an [epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor] while you switch to chemotherapy,” said Solange Peters, MD, PhD, Head of the Thoracic Malignancies Program at the University of Lausanne, Switzerland, at the European ...
Oncology on Canvas Art Competition Winning Artwork
The 10th anniversary of the Lilly Oncology On Canvas Art Competition was celebrated with the presentation of awards and display of winning entries in New York’s Grand Central Terminal on October 23, 2014. First-, second-, and third-place winners were published in the November 15 issue of The ASCO...
Raising Consciousness About Drug Costs: A Call to Action
As medical oncologists working in chemotherapy utilization management (Oncology Analytics, Inc), my colleagues and I find ourselves daily in the center of the drug-cost maelstrom. While it is encouraging to see that more attention is being paid in the popular and medical press to this...
Unique Barriers to Pain Control
I read with great interest your interview with Virginia LeBaron, PhD, APRN, about barriers to adequate pain control (“Despite Growing Awareness, the Global Crisis of Untreated Cancer Pain Persists,” The ASCO Post, October 15, 2014). Having served as the medical director of a hospice, I am...
Huntsman Cancer Institute Investigator Receives Leadership Award from the National Cancer Institute
Neeraj Agarwal, MD, a Huntsman Cancer Institute investigator and Associate Professor of Medicine at the University of Utah, has received the 2014 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). This highly competitive award recognizes exceptional cancer...
NCCN Publishes 20th Annual Guidelines in NSCLC, Reflecting Advances in Screening, Diagnosis, Radiology, and Systemic Therapies
The National Comprehensive Cancer Network (NCCN) has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC), one of the eight original NCCN Guidelines published in November 1996. “Since the first NCCN...
Expect Questions From Patients
Screening for thyroid cancer should be discouraged to prevent an “epidemic of diagnosis”—like the one occurring in South Korea—from happening in the United States and other countries, according to the authors of an analysis of the South Korean screening program. That study was published in The New...
South Korean Study Sparks Warnings About the Hazards of Overscreening
An “epidemic of diagnosis” of thyroid cancer is occurring in South Korea and “absolutely could happen here,” according to H. Gilbert Welch, MD, MPH, Professor of Medicine at the Dartmouth Institute for Health Policy and Clinical Practice, Hanover, New Hampshire. Dr. Welch is coauthor of an article...
Fred Hutchinson Cancer Research Center Recruits D. Gary Gilliland, MD, PhD as New President and Director
Fred Hutchinson Cancer Research Center announced that it has named D. Gary Gilliland, MD, PhD, an expert in cancer genetics and precision medicine as its new President and Director. He will take the helm as the Center’s new leader on January 2. Dr. Gilliland comes to Fred Hutchinson from the...
Yale Cancer Center’s Dr. Susan Mayne Appointed to FDA Position
Susan T. Mayne, PhD, C-EA, Winslow Professor of Epidemiology; Associate Director for Population Sciences at Yale Cancer Center; and Chair of the Department of Chronic Disease Epidemiology at Yale School of Public Health, has been appointed to the position of Center Director of the Center for Food...
ACCC Honors Nicholas J. Petrelli, MD, With 2014 Clinical Research Award
Nicholas J. Petrelli, MD, FACS, the Bank of America endowed Medical Director of Christiana Care’s Helen F. Graham Cancer Center & Research Institute, Newark, Delaware, received the 2014 Clinical Research Award from the Association of Community Cancer Centers (ACCC) in recognition of his...
Rolf-Detlef Treede, MD, PhD, Elected IASP President
Members of the International Association for the Study of Pain (IASP) have elected Rolf-Detlef Treede, MD, PhD, as the organization’s new president. Dr. Treede is Chair of Neurophysiology and Managing Director of the Center for Biomedicine and Medical Technology Mannheim at Heidelberg University in ...
FDA Approves Extended-Release, Single-Entity Hydrocodone Product With Abuse-Deterrent Properties
The U.S. Food and Drug Administration (FDA) today approved hydrocodone bitartrate (Hysingla ER), an extended-release opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The product...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Chevalier Jackson, MD, Performing Bronchoscopy, Philadelphia, Circa 1920
The bronchoscope was first used for extracting foreign bodies and the evaluation of infectious processes, especially abscesses. By the end of the twentieth century, the bronchoscope had been determined the single most useful tool for accurate diagnosis of lung cancer. It allowed for the collection...
Fluoroscopy for Lung Disease, Boston, 1903
When Thomas Alva Edison, the Wizard of Menlo Park, heard of Roentgen’s discovery of the x-ray, he directed his research staff to create x-ray tubes and better screens on which to view the images. Edison owned America’s first industrial research laboratory and could easily supply the know-how,...
Preoperative Rodent Cancer: Patient of Charles Moore, MD, Albumen Print, London, 1864
A disease more repulsive and distressing can hardly be conceived than a Rodent Cancer of the face. Commencing in some trifling manner in the skin, and then sometimes producing so little irritation as scarcely to attract notice, it spreads abroad in all directions with a slow but unswerving advance. ...
Bevacizumab Plus Chemotherapy in Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 14, 2014, bevacizumab (Avastin) in combination with...
2014 Oncology Meetings
DECEMBER Society of Urologic Oncology 15th Annual MeetingDecember 3-5 • Bethesda, Maryland For more information: http://suonet.org/meetings/2014/default.aspx UICC World Cancer CongressDecember 3-6 • Melbourne, AustraliaFor more information: www.worldcancercongress.org 1st Rome International Meeting ...
ASTRO Commends Medicare’s Proposed Decision to Cover Annual Low-Dose CT Screening for High-Risk Lung Cancer Patients Aged 55–74
The American Society for Radiation Oncology (ASTRO) praised the November 11, 2014, decision proposal by the Centers for Medicare and Medicaid Services (CMS) to provide coverage for annual lung cancer screening via low-dose computed tomography (CT) screening for those at highest-risk for lung...
A Good Life, All the Way to the Very End
BOOKMARKTitle: Being MortalAuthor: Atul Gawande, MDPublisher: Metropolitan BooksPublication date: October 7, 2014Price: $26.00; hardcover, 304 pages Mortality is the invisible observer in the oncology exam room. When people hear the three words, “You have cancer,” they see their world as they...
Memorial Sloan Kettering Team Discovery Advances Understanding of Immunotherapy’s Successes—and Its Failures
A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to the CTLA-4 blocking antibody ipilimumab (Yervoy), an immunotherapy drug, while others do not. A...
ASH Awards New Bridge Grants to Help Alleviate Pain of Federal Funding Cuts
In November, the American Society of Hematology (ASH) announced the names of seven recipients of its Bridge Grant awards. These 1-year, $150,000 awards provide critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the National...
The American Society of Hematology Elects New Leadership
The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee, the governing body of the organization, for terms beginning after the 2014 ASH Annual Meeting, which will be held December 6–9 in San Francisco. Kenneth C. Anderson, MD, will...
Expert Point of View: Joan M. Teno, MD, MS, and Pedro L. Gozalo, PhD
Joan M. Teno, MD, MS, and Pedro L. Gozalo, PhD, of the Brown University School of Public Health, Providence, Rhode Island, commented on end-of-life care in an editorial accompanying the JAMA study by Obermeyer et al. “As financial incentives change in the U.S. health-care system, valid measures of ...
Use of Hospice Care by Medicare Patients Associated With Lower Rate of Hospitalization, ICU Admission, Invasive Procedures, and Costs
Medicare patients with poorprognosis cancers who received hospice care had significantly lower rates of hospitalization, intensive care unit (ICU) admissions and invasive procedures at the end of life, along with significantly lower health care expenditures during the last year of life, according...
How the Earlier Introduction of Palliative Care Improves Quality of Life for Patients With Advanced Cancer
A 4-year study1 involving 461 patients with advanced stages of lung, gastrointestinal, genitourinary, breast, and gynecologic cancers has found that providing early outpatient palliative care vs standard oncology care alone improved quality of life and patient satisfaction. The study participants...
Proteome-Scale Map of the Human Interactome Network Created
Researchers have produced a new largest-scale map of human protein interactions that will better enable scientists to trace how genetic changes lead to diseases ranging from cancer to Huntington’s disease. The expanded map, published in the journal Cell,1 is about 30% larger than the combination of ...
Helping Adolescents and Young Adults Cope With Cancer
Each year, about 70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the United States, almost six times the number of cases diagnosed in children up to 14 years of age. While overall cancer survival rates continue to rise—according to the American Cancer Society, there are...
Scientists Develop New Approach to Treating HPV-Related Cervical Cancer
Cidofovir, an antiviral drug that is well established as a treatment for infection of the retina in people with AIDS, has been shown to be effective in combination with chemoradiation in a phase I study of women with human papillomavirus (HPV)-related cervical cancer. The study results were...
Treating Brain Cancer in 2014
While primary malignant brain tumors account for only 2% of all adult cancers, these deadly neoplasms cause severe cancer-related disability; the 5-year survival rates for brain tumors rank third lowest among all cancers, with those for pancreas and lung cancers being first and second lowest,...
Study Finds Wide Variation in Quality, Content of Clinical Cancer Guidelines
What’s the best way to treat rectal cancer? Consult any of five top clinical guidelines for rectal cancer and you will get a different answer, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center. Their findings were published online in the journal...
HDAC Inhibitors and Triple Therapy in Relapsed Myeloma
The use of histone deacetylase (HDAC) inhibitors as human cancer therapy has focused on the impact of these agents on epigenetic regulation and gene transcription. However, the use of HDAC inhibitors in myeloma may be working through a different mechanism. Specifically, HDAC6 is known to regulate...
Cancer-Killing Virus Plus Chemotherapy Studied in Recurrent Ovarian Cancer
In 6 out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and 5-year survival is only 27%. A new study suggests that a cancer-killing virus combined with a chemotherapy drug might safely and effectively treat advanced or recurrent forms of the disease. Researchers at The Ohio...
Advancing ASCO’s Commitment to Quality to Ensure That Every Patient Receives the Highest Level of Cancer Care
On December 3, 2014, Robert S. Miller, MD, FACP, FASCO, will start his new position as Medical Director of ASCO’s Institute for Quality (iQ). Established in 2012 to oversee the development of clinical practice guidelines, the Quality Oncology Practice Initiative (QOPI), the QOPI Certification...
With New Innovator Award, Biomedical Engineer to Study How Ovarian Cancer Spreads
With approximately 22,000 diagnoses annually in the United States, ovarian cancer isn’t among the most commonly occurring cancers. Yet, the mortality rate for women who have ovarian cancer hovers above 60%. For Pamela Kreeger, PhD, a University of Wisconsin–Madison Assistant Professor of Biomedical ...
From ‘Clinical Judgment’ to Evidence-Based Medicine: Thoughts on the ASCO/CCO Guideline in Metastatic Castration-Resistant Prostate Cancer
We are witnessing unprecedented progress in the development of therapy for patients with metastatic castration-resistant prostate cancer. The U.S. Food and Drug Administration (FDA) has issued 13 approvals since 1996 for agents that have demonstrated an impact on overall survival, pain, or...
Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: ASCO/CCO Clinical Practice Guideline
The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline was published in the Journal of Clinical...
Sigmoidoscopy or Colonoscopy for Colorectal Cancer Screening: Is It Still the Question?
Mortality from colorectal cancer remains a public-health concern, being the second leading cause of cancer-related death for men and women combined. The major preventive measure for colorectal cancer is to screen for and remove adenomatous polyps. Average-risk individuals (ie, those who do not have ...
New Imaging Technique Identifies Receptors for Targeted Cancer Therapy
Dartmouth researchers have developed a fluorescence imaging technique that can more accurately identify receptors for targeted cancer therapies without a tissue biopsy. They report on their findings in a recently published article in Cancer Research.1 “Protein overexpression is a hallmark of...
The Harvard Global Equity Initiative: From Research to Policy
The Harvard Global Equity Initiative is a research program at Harvard University that is dedicated to promoting equitable global development, with a strong emphasis on health-care issues. This initiative brings together scholars, policymakers, advocates, and practitioners from around the world to...
FDA Grants Orphan Drug Designation to BGB324 for Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BGB324 for the treatment of acute myeloid leukemia (AML). BGB324 is a first-in-class, highly selective small-molecule inhibitor of the Axl receptor tyrosine kinase. It blocks the epithelial-mesenchymal transition...
Power Behind ‘Master’ Gene for Cancer Discovered
A study at The University of Texas MD Anderson Cancer Center, Houston, led by Mong-Hong Lee, PhD, Professor of Molecular and Cellular Oncology, has demonstrated the significance of CSN6 in regulating Myc which may well open up a new pathway for treating and killing tumors. The study results are...
CAR T-Cell Therapy in Cancer: Driving Toward the Clinic
Chimeric antigen receptor (CAR) T-cell therapy represents a novel and promising therapeutic advance in cancer.1,2 It constitutes a form of personalized therapy that harnesses adoptive cell transfer through genetic engineering of autologous T cells. The initial step in this therapeutic paradigm...
Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticancer drugs. The combination of bevacizumab (Avastin) and erlotinib (Tarceva) produced excellent...
Having Dependent Children Motivates Parents With Advanced Cancer to Pursue More Aggressive, Life-Extending Treatments
Findings from a pilot study of 42 parents with advanced cancer indicate that parental status is an important factor in treatment decision-making. When asked how having children influences their treatment decisions, the majority of parents (64%) responded that being a parent motivates them to pursue ...
Medicare Part D Low-Income Subsidy Program Improves Adherence to Hormone Therapy After Breast Cancer Surgery
Findings from a study of more than 23,000 women suggest that the Medicare Part D Extra Help program, which provides low-income subsidies for medications, improves adherence to hormone therapy after breast cancer surgery in all racial/ethnic groups and reduces racial/ethnic disparities. The study,...
ASH Pairs Hematologists From Developing and Developed Nations for Global Training Program
The American Society of Hematology (ASH) recently announced the 20 hematologists and other medical professionals selected to participate in the 2014 ASH Visitor Training Program. This program provides talented hematologists, scientists, and laboratory staff from developing countries the opportunity ...
FDA Approves Bevacizumab Plus Chemotherapy for Platinum-Resistant, Recurrent Ovarian Cancer
The U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The approval is ...
2014 Featured Columnists
The ASCO Post wishes to acknowledge and thank all contributors to the publication during 2014. Here we recognize those who shared their personal thoughts in our Op-Ed department. If you are interested in contributing to The ASCO Post in 2015, write to editor@ASCOPost.com. Robert Peter Gale, MD,...
